What question did this study set out to answer?

This research aims to design and evaluate new aromatic inhibitors for breast cancer treatment that are less toxic and have higher efficacy.

Design, Synthesis, and Biological Evaluation of Benzimidazole‐Pyrazole Hybrids as Aromatase Inhibitors for Breast Cancer Therapy

View Full Paper

Ask AI

Bookmark

Authors

Evaluates benzimidazole-pyrazole hybrids for breast cancer, revealing promising new inhibitors that may reduce toxicity.

This research aims to design and evaluate new aromatic inhibitors for breast cancer treatment that are less toxic and have higher efficacy.
Designed and synthesized 12 benzimidazole-pyrazole hybrids.
Characterized compounds using infrared spectroscopy and nuclear magnetic resonance spectroscopy.
Evaluated compounds for cytotoxicity using the MTT assay against the MCF-7 cell line.
Assessed aromatase inhibitory activity using a fluorometric assay.
Conducted molecular docking studies and ADMET analysis.
Compounds 5g and 5i showed the highest cytotoxicity with the lowest IC50 values.
Compound 5g demonstrated the greatest aromatase inhibitory activity among tested compounds.
Molecular docking revealed higher binding affinity of compounds 5g and 5i compared to letrozole.
ADMET analysis confirmed favorable drug-likeness of the synthesized hybrids.

Sharma et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark